RxDoctor Payments Data

Nilsa Sanchez, MD

Geriatric Medicine · Puerto Nuevo, PRNPI 1174500169

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.6% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by AstraZeneca at 33.1% of the total. Reporting peaked in 2022 at $337 and has fallen 81.5% since, to $62 in 2025.

$979in general payments, 2019–2025

Across 50 payments — averaging $19.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$324
  • GSK$161
  • Lilly USA, LLC$141
  • Novo Nordisk$108
  • Bayer$104
  • Xeris Pharmaceuticals, Inc.$38
  • plus $103 from 5 others

What the payments were for

  • Food & beverage$96699%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$979 in reported general payments places this provider in the 75th percentile of 76 geriatric medicine providers in Puerto Rico.

See all geriatric medicine providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$11,057
Medicare patients
29
Services billed
163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$92,797
FarxigaDapagliflozin Propanediol34$52,202
JardianceEmpagliflozin30$46,792
OzempicSemaglutide20$33,137
TrulicityDulaglutide26$27,364
MounjaroTirzepatide12$22,173
XareltoRivaroxaban15$19,732
EntrestoSacubitril/Valsartan17$18,803
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$18,278
Fluticasone-SalmeterolFluticasone Propion/Salmeterol81$17,489
CreonLipase/Protease/Amylase11$13,814
SymbicortBudesonide/Formoterol Fumarate23$9,532
Albuterol Sulfate HfaAlbuterol Sulfate272$7,668
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog16$7,229
Wixela InhubFluticasone Propion/Salmeterol36$6,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$92,79784 claims
AstraZenecaFarxiga, Symbicort$324$61,73557 claims
Lilly USA, LLCTrulicity, Mounjaro$141$49,53738 claims
Novo NordiskOzempic$108$33,13720 claims
Johnson & JohnsonXarelto$23$19,73215 claims
GSKTrelegy Ellipta$161$18,27814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 76 geriatric medicine providers in Puerto Rico.

Other geriatric medicine in Puerto Nuevo

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →